诺和诺德终止开发每周1次司美格鲁肽口服片剂

医药魔方
07 May

5月7日,诺和诺德在发布2025年一季度业绩时透露,基于投资组合考虑,已在4月终止开发每周1次司美格鲁肽口服片剂。此外,诺和诺德已基于III期ESSENCE研究的第一部分结果在欧美递交司美格鲁肽2.4mg用于治疗伴中晚期肝纤维化(F2-F4)代谢功能障碍相关性脂肪性肝炎(MASH)的上市申请,并且该申请已获得FDA授予优先审评资格。在ESSENCE研究第一部分中,治疗72周后,司美格鲁肽2.4mg...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10